department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Zykadia · pharmadog

pharmadog
drugs
Zykadia

drug

patient view →

ceritinib

Marketedupdated 2mo ago

by $NVS NOVARTIS AG

Approved

community read0 votes

indications

investigational

NSCLC

all catalysts(1)

phase 2 completion · 1

News(0)

no news has mentioned this drug yet

brand

Zykadia

generic

ceritinib

indication

Non-Small Cell Lung Cancer

phase

marketed

phase 2 completion

Beijing Sanbo Brain Hospital — ceritinib (Phase II Trial Completion)

Data sources

ClinicalTrials.gov

last refreshed 32m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Patent cliff

source: FDA Orange Book

first barrier falls

Nov 20, 2027

~1.4 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (15)

Dec 13, 2037method-of-use (U-3096)US 12357630
Feb 2, 2032method-of-use (U-1179)US 8703787
Feb 2, 2032method-of-use (U-1179)US 8703787
Jan 18, 2032compositionUS 9309229
Jan 18, 2032compositionUS 9309229
Jun 29, 2030compositionUS 80394794.0y
Jun 29, 2030compositionUS 80394794.0y
Apr 29, 2028compositionUS 79645921.8y
Apr 29, 2028compositionUS 79645921.8y
Nov 20, 2027method-of-use (U-1179)US 83779211.4y
Nov 20, 2027method-of-use (U-1179)US 83779211.4y
Nov 20, 2027compositionUS 83994501.4y
Nov 20, 2027compositionUS 83994501.4y
Apr 25, 2026compositionUS 7893074
Apr 25, 2026compositionUS 7893074

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

🐶 often sniffed alongside

top 2

tagOncology2 co-mentions · 1 sources
companyBeijing Sanbo Brain Hospital1 co-mentions · 1 sources

Trials studying ceritinib

phase1Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Canceractive not recruitingn=57
phase4Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Studyactive not recruitingn=233
—Managed Access Programs for LDK378, Ceritinibno longer available
phase1Next Generation Personalized Neuroblastoma Therapyterminatedn=66
phase1Study of Trametinib + Ceritinib in Patients With Unresectable Melanomacompletedn=27
phase2Pediatric Precision Laboratory Advanced Neuroblastoma Therapyrecruitingn=500
—A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.completedn=5,279
phase3LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinibcompletedn=231

more trials →